ANGLE is a world leading liquid biopsy company with pioneering products in cancer diagnostics and foetal health. ANGLEs lead product is the Parsortix cell separation system, which can capture very rare cells from blood. This includes circulating tumour cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient's cancer for personalised cancer care. ANGLE has launched a product for the research market and has secured CE Mark regulatory approval for the clinical market in Europe. The FDA authorization is in process. ANGLE is also undertaking clinical studies, the first on of which is in Ovarian Cancer for a clinical application to triage women having surgery for an abnormal pelvic mass to identify those with ovarian cancer. 200 patient clinical studies in both Europe and the US have reported positive headline data and the test is being optimized before moving to validation studies. ANGLE has announced the acquisition of certain assets of Axela Inc, a novel multiplex diagnostic tool for the analysis of DNA, RNA and proteins.